Betta Pharmaceuticals (SHE: 300558) announced that its partner EyePoint Pharmaceuticals (NASDAQ: EYPT) disclosed data from LUCIA, the second pivotal Phase III clinical trial evaluating EYP‑1901 (DURAVYU), an investigational vorolanib ophthalmic formulation delivered as an intravitreal insert, for the treatment of wet age‑related macular degeneration (wAMD). The study did not meet its primary endpoint of statistical non‑inferiority versus aflibercept 2 mg every eight weeks, although key secondary endpoints — including safety, treatment‑burden reduction, proportion of supplement‑free patients, and anatomical control — were all met.
Trial Snapshot
| Item | Detail |
|---|---|
| Discloser | EyePoint Pharmaceuticals (NASDAQ: EYPT); announced by partner Betta Pharmaceuticals (SHE: 300558) |
| Candidate | EYP‑1901 / DURAVYU – vorolanib ophthalmic formulation, intravitreal insert |
| Study | LUCIA – second pivotal Phase III trial in wAMD |
| Design | Randomized, double‑blind, aflibercept‑controlled |
| Regimens Compared | DURAVYU 2.7 mg every six months vs. aflibercept 2 mg every eight weeks |
| Primary Endpoint | Non‑inferiority in mean change from baseline in best corrected visual acuity (BCVA) at Weeks 52 and 56 – not met |
| Secondary Endpoints | Safety, reduction in treatment burden, proportion of supplement‑free patients, anatomical control – all met |
| Numeric Results | Not disclosed |
Drug Profile & Mechanism of Action
- Molecule: Vorolanib, a small‑molecule tyrosine kinase inhibitor formulated for ocular use as EYP‑1901 (DURAVYU).
- Delivery: A sustained‑release intravitreal insert designed for every‑six‑months dosing, versus the every‑eight‑weeks injection cadence of the aflibercept control.
- Indication: Wet age‑related macular degeneration (wAMD), a leading cause of vision loss in older adults driven by abnormal retinal neovascularization.
- Trial Position: LUCIA is the second pivotal Phase III readout for DURAVYU in wAMD; results from the first pivotal trial and its relationship to this readout were not disclosed.
Clinical Evidence – LUCIA Phase III Trial
| Endpoint | Outcome |
|---|---|
| Primary – BCVA Non‑Inferiority at Weeks 52 and 56 | Not met – DURAVYU patients showed visual acuity improvement, but statistical non‑inferiority vs. aflibercept 2 mg was not demonstrated |
| Safety (key secondary) | Met |
| Reduction in Treatment Burden (key secondary) | Met |
| Proportion of Supplement‑Free Patients (key secondary) | Met |
| Anatomical Control (key secondary) | Met |
| BCVA Change Values / Margins | Not disclosed |
In LUCIA, subjects in the DURAVYU treatment group demonstrated visual acuity improvement; however, the study failed to demonstrate statistical non‑inferiority compared with the aflibercept 2 mg control group on the mean change in BCVA from baseline at Weeks 52 and 56. All prespecified key secondary endpoints were met, supporting the insert’s profile in safety, dosing convenience, and disease control despite the primary endpoint shortfall.
Market Impact & Outlook
- Primary Endpoint Shortfall: Missing non‑inferiority on BCVA against aflibercept complicates the efficacy narrative for DURAVYU’s six‑month dosing proposition; the magnitude of the miss and its regulatory implications were not disclosed.
- Durability Story Intact: The met secondary endpoints — supplement‑free patients, treatment‑burden reduction, and anatomical control — align with the value proposition of a sustained‑release insert for patients seeking fewer injections.
- Competitive wAMD Landscape: The market anchors on anti‑VEGF standards including aflibercept and longer‑acting entrants; positioning of a twice‑yearly insert will hinge on how regulators and payers weigh non‑inferiority failure against convenience and durability benefits.
- Partner Exposure: Both EyePoint (NASDAQ: EYPT) and Betta Pharmaceuticals (SHE: 300558) carry stakes in the program’s trajectory; next steps, including any regulatory filing strategy or further data analysis, were not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding EYP‑1901 (DURAVYU), including its development and potential role in treating wet AMD. DURAVYU is investigational and has not been approved by any regulatory authority for any indication. The LUCIA trial did not meet its primary endpoint, and actual outcomes — including regulatory review and commercial prospects — may differ materially based on data interpretation, regulatory requirements, and competitive dynamics.-Fineline Info & Tech
